CD274 and interstitial lung disease: In a systematic review and meta‐analysis of trials on the incidence of ILD with anti‐PD‐1 antibody and anti‐PD‐L1 antibody, it was reported that treatment‐naïve patients had a significantly higher prevalence of ILD than previously treated patients (4.3% vs. 2.8%, P = 0.03).19 Thus, using ICI in first line therapy for patients with preexisting ILD may result in a high rate of drug‐induced ILD occurrence, so caution should be exercised.